Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Rapid Responses to:
|
|
Rapid Responses published:
|
|
|||
|
David JR Hutchon, Consultant Obstetrician and Gynaecologist Darlington Memorial Hospital. DL3 6HX
Send response to journal:
|
The licensing of cord blood collection and storage by the Human Tissue Authority is very welcome. (1) This regulation will ensure that care workers are not distracted from the immediate and direct care of the mother and baby at birth. As Belinda Phipps of the NCT points out, care must be taken to ensure that the baby is not deprived of its own cord and placental blood. Peter Braude has also pointed out that collection conditions can influence the likelihood of stem cells being obtained from the umbilical cord blood samples collected. Volume is one of these conditions and it is undisputed that early cord clamping increases the residual volume of blood in the cord and placenta, and increases the chance of successful collection. The RCOG expert group on cord blood chaired by Professor Braude conclude that there should be no alteration in ‘usual management’ of the third stage. (2) This assumes that current ‘usual management’ of the third stage is optimal. The recent NICE intrapartum care guideline recommends women be offered an “active management package” or a physiological third stage. (3) Early cord clamping is included as an essential element of this package. However the inclusion of early cord clamping is without an evidence base, and encourages the usual practice of early cord clamping at birth, to the detriment of the baby. (4) I trust that the licensing authority will take into account the health of the baby (5) within its regulations for cord blood collection. David J R Hutchon FRCOG
References Competing interests: None declared |
|||